Understanding an inherited predisposition to hematologic malignancies, and how a pre-cancerous condition becomes cancer will allow for early intervention and cancer prevention.
Precision Prevention & Early Detection
Cancer Research Ideas - Precision Prevention & Early Detection (Archived)
Advances in genomic technologies should lead to improved prevention and early detection strategies. As we develop a better understanding of common genetic variants that are associated with higher or lower risk of certain cancers, we may be able to use that knowledge to identify individuals who may or may not benefit from prevention strategies. And techniques to analyze bits of tumor DNA (and other molecules) that are released into the blood and other body fluids may enable noninvasive screening for very early cancers.
The submission period for Precision Prevention & Early Detection ideas ended on July 1. However, we encourage you to sign up for regular e-mail updates about the National Cancer Moonshot Initiative at the Cancer Moonshot Milestones web page.
Colorectal cancer (CRC) subtypes have distinct genotypes and prognoses. Practical clinical laboratory tests to recognize CRC subtypes are needed to allow certain early-stage CRCs to receive consolidation therapy to prevent recurrence and death.
Data aggregation techniques are powerful tools to reduce the information burden that is discouraging physicians from utilizing point-of-care equipment in their daily practice.
Groups are working on deep sequencing to find tiny amounts of circulating biomarkers of early cancer and its malignant potential. Independent validation of these methods is essential to realizing the full potential of such early detection methods.
We've identified many genetic mutations that confer significant risk and identify more each year. But this knowledge is squandered if insurers won't pay for appropriate genetic testing/counseling and early detection. That should be required.
The idea is to develop a non-invasive early cancer detection technology using super para-magnetic relaxometry applied to the detection of human diseases, such as cancer. We want to show that the technology is both highly specific and very sensitive.
Our research program will demonstrate that circulating DNA released from tumors after high-dose radiation (SBRT, SRS) can be used as an anatomically-directed liquid biopsy to aid in the diagnosis and management of cancer.
Race and socioeconomic status are associated with distance from and limited access to high-quality cancer care and worse outcomes. The Society of Gynecologic Oncology recommends intervention strategies to close the geography disparity gap.
An app for family history of cancers like ancestry.com pedigree. - Submitted on behalf of William D. Freeman, M.D., Mayo Clinic, Jacksonville, Florida
Hemoglobin, ferritin, total iron binding capacity, iron saturation, Hepcidin-25 and Transferrin receptor detects anemia, hemolysis, hemochromatosis. Hemochromatosis is diagnosed by genetic testing. Test for MCH, MCV and EVF to screen for Thalassemia.
Many cancers could be prevented by modifying behaviors and increasing cancer screening rates. General messages promoting behavior change have not been effective. Specifically targeting populations at increased risk may improve success.
Recent research suggests that the deadliest form of ovarian cancer, high grade serous adenocarcinoma, actually originates in the fallopian tubes. The fallopian tubes can be accessed in a minimally invasive manner using highly specialized devices.
Although medical diagnostics can evaluate intracellular characteristics of tumors (e.g., genomics, proteomics), we lack diagnostic methods that interrogate the extracellular tumor microenvironment including extracellular hypoxia and acidosis.
Obesity rates continue to rise, driving up the incidence of obesity-driven cancers. In particular, vulnerable groups include Hispanics and Native Americans. Primary prevention strategies that target individual risk and early detection are essential.
We propose to develop agents that will provide targeted therapy, and analysis of therapeutic response, in breast and ovarian cancers within the Latina population.